All In Biotech

Drug Trial Radar · NCT04697641

Helicobacter Pylori Eradication in Functional Dyspepsia

Efficacy of Helicobacter Pylori Eradication on Symptoms of Functional Dyspepsia - A Randomised Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jan 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

202

Actual

Start

Sep 1, 2017

Primary completion

May 31, 2019

Study completion May 31, 2019

Sponsor

Lead sponsor
Sir Ganga Ram HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to study benefit of eradicating Helicobacter Pylori in patients with functional dyspepsia as compared to symptomatic treatment only. Helicobacter pylori positive patients with Functional Dyspepsia will be divided into two study groups, one will receive Helicobacter pylori eradication therapy and other will receive symptomatic treatment. Symptom relief based on Likert scale will be compared in both groups.

Conditions

  • Dyspepsia
  • Helicobacter Pylori Infection

Interventions

  • Clarithromycin 500mgDrug

    Clarithromycin 500 mg twice a day for two weeks

  • Amoxicillin 1000 MGDrug

    Amoxicillin 1000mg twice a day for two weeks

  • Pantoprazole 40mgDrug

    Pantoprazole 40 mg or equivalent for eight weeks

  • LevosulpirideDrug

    Levosulpiride 25 mg as and when required before meals

  • AcotiamideDrug

    Acotiamide 100mg as when required before meals

  • ItoprideDrug

    Itopride 50mg as when required before meals

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment SuccessTime frame: Six months after the completion of intervention

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Gastroenterology & Hepatology, Sir Ganga Ram Hospital

    New Delhi, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.